Dermatologic was Castle Biosciences’s largest product and service line in fiscal 2025, bringing in $216.37M of $344.23M (63%).
| Product and Service | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Dermatologic | $124.81M | $183.38M | $257.00M | $216.37M | ||
| Non Dermatologic | $12.23M | $36.41M | $75.07M | $127.86M | ||
| Other | — | — | — | — | ||
| Total | $137.04M | $219.79M | $332.07M | $344.23M |
Castle Biosciences brought in $344.23M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 3.7% from $332.07M in fiscal 2024. Dermatologic was the largest at $216.37M (62.9%), ahead of Non Dermatologic at $127.86M (37.1%).
Compared with fiscal 2024, Non Dermatologic grew 70.3% to $127.86M, while Dermatologic fell 15.8% to $216.37M. From fiscal 2022 to 2025, combined revenue from these lines grew from $137.04M to $344.23M, a compound annual growth rate of 35.9%. Dermatologic's share of the total fell from 91.1% to 62.9%.
Castle Biosciences (CSTL) reports its revenue by product and service. In fiscal 2025, Dermatologic was its largest product and service line, bringing in $216.37M (62.9% of the total), followed by Non Dermatologic at $127.86M (37.1%).
Dermatologic was Castle Biosciences' largest product and service line in fiscal 2025, bringing in $216.37M, or 62.9% of the $344.23M total across its two product and service lines.
Non Dermatologic grew faster than Dermatologic in fiscal 2025, up 70.3% from $75.07M to $127.86M. Dermatologic fell 15.8% to $216.37M.
Every figure comes from Castle Biosciences' annual financial filings, as reported. Each line keeps the name Castle Biosciences gives it, and years follow its fiscal calendar.
Castle Biosciences' revenue by product and service goes back to fiscal 2020, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.